Hyperkalemic changes during spironolactone therapy for cirrhosis and ascites, with special reference to hyperkalemic intermittent paralysis.
D001201:Ascites / Q000188:drug therapy*; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007677:Kidney Function Tests; D007684:Kidney Tubules / Q000187:drug effects; D008103:Liver Cirrhosis / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D008297:Male; D008875:Middle Aged; D010243:Paralysis / Q000139:chemically induced*; D011188:Potassium / Q000097:blood / Q000652:urine; D012964:Sodium / Q000097:blood / Q000652:urine; D013148:Spironolactone / Q000009:adverse effects* / Q000494:pharmacology
D004232:Diuretics; D013148:Spironolactone; D012964:Sodium; D011188:Potassium